Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to $532000.0.

  • Rockwell Medical's Share-based Compensation rose 6573.21% to $532000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 5434.4%. This contributed to the annual value of $1.3 million for FY2024, which is 3862.66% up from last year.
  • Rockwell Medical's Share-based Compensation amounted to $532000.0 in Q3 2025, which was up 6573.21% from $382000.0 recorded in Q2 2025.
  • Over the past 5 years, Rockwell Medical's Share-based Compensation peaked at $532000.0 during Q3 2025, and registered a low of -$236000.0 during Q1 2021.
  • Over the past 5 years, Rockwell Medical's median Share-based Compensation value was $309000.0 (recorded in 2023), while the average stood at $254789.5.
  • As far as peak fluctuations go, Rockwell Medical's Share-based Compensation crashed by 12524.06% in 2021, and later skyrocketed by 21855.67% in 2023.
  • Over the past 5 years, Rockwell Medical's Share-based Compensation (Quarter) stood at $385000.0 in 2021, then plummeted by 42.86% to $220000.0 in 2022, then dropped by 0.91% to $218000.0 in 2023, then skyrocketed by 75.23% to $382000.0 in 2024, then surged by 39.27% to $532000.0 in 2025.
  • Its Share-based Compensation stands at $532000.0 for Q3 2025, versus $382000.0 for Q2 2025 and $445000.0 for Q1 2025.